Telomeres both reflect and limit the replicative lifespan of normal somatic cells. Immature sub-populations of human CD34 þ 38À hematopoietic stem cell (HSC) can be identified in vitro based on their growth kinetics and telomere length. Fluorescence in situ hybridization and flow cytometry (flow-FISH) has been used to characterize telomere length dynamics as a surrogate marker for HSC turnover in vivo. Investigations in normal steady-state hematopoiesis provided the basis for follow-up studies in model scenarios characterized by increased HSC turnover. Disorders with underlying malignant transformation of HSC (e.g., chronic myeloid leukemia (CML)) can be discriminated from disease states with increased HSC turnover rates secondary to depletion of the stem cell compartment, for example, as in defined bone marrow failure syndromes. In some of these model scenarios, the degree of telomere shortening can be correlated with disease duration, disease stage and severity as well as with response to diseasemodifying treatment strategies. Whether increased telomere shortening represents a causal link between HSC turnover, replicative senescence and/or the induction of genetic instability in acquired HSC disorders remains to be shown. However, data from congenital disorders, like dyskeratosis congenita (DKC), suggest that disturbed telomere maintenance may play a role for replicative exhaustion of the HSC pool in vivo.
Introduction

Telomeres and telomerase in replicative senescence and cell immortalization
In vertebrates, the ends of chromosomes are capped by telomeres, which consist of hundreds to thousands of tandem repeats of the sequence T 2 AG 3 1,2 and associated proteins. 3 Telomeres are important in maintaining the integrity of chromosomes, 4 protecting them against fusion events 5 as well as mediating chromosomal attachment to the nuclear matrix. 6 Moreover, owing to the incomplete replication of the lagging strand by conventional DNA polymerase during chromosomal replication, the 5 0 end of the daughter strand will shorten with each cell division. 7, 8 Experimental evidence indicates that the length of telomeres decreases with aging in normal human somatic tissues in vivo and in in vitro cultured fibroblasts. [9] [10] [11] [12] These observations have led to a model in which telomere length reflects the mitotic history of somatic cells and is predictive of their residual replicative capacity. 13 Further support for this hypothesis has come from the discovery of the ribonucleoprotein enzyme telomerase that is able to synthesize terminal TTAGGG telomeric repeats and thus to extend telomeres de novo.
14 Telomerase activity is expressed in cells of the germline, thereby protecting them against telomere shortening. In human germ line cells, telomeres are typically maintained at about 15 kilobase pairs (kbp). 15 In contrast, telomerase is not expressed in most normal somatic cells in culture, which is in line with the observation that these cells have a finite lifespan and undergo cellular replicative senescence after 40 to 80 population doublings (PDs). 16 Finally, high levels of telomerase activity have been detected in transformed cell lines and malignant tumors by the sensitive telomere repeat amplification protocol (TRAP) assay. 17 It has been postulated that the process of immortalization typically requires the reactivation of telomerase for telomere stabilization and maintenance in tumor cells. 18, 19 Ten years ago, the genes encoding the human telomerase catalytic subunit (hTERT) [20] [21] [22] and the human RNA template component (human telomerase RNA (hTR) or hTERC) 23 were identified. Ectopic expression of hTR and hTERT induced telomerase activity in telomerase-negative human cells. 24, 25 Moreover, experiments have shown that transfection of the hTERT gene can result in the extension of telomeres and increased proliferative lifespan of fibroblast clones of retinal pigment epithelial cells 26, 27 and hepatocytes. 28, 29 The 'telomerized' cells appeared indistinguishable from young normal cells and did not show signs of chromosomal aberrations or cellular transformation. 28, 30, 31 In summary, expression of telomerase in normal somatic cells was able to prevent replicative senescence providing compelling evidence for a direct linkage between telomere shortening and replicative lifespan of cells.
Another important implication from these experiments was that overexpression of the telomerase catalytic subunit hTERT is obviously required but not sufficient to transform normal cells into malignant cells. Hahn et al. 32 reported that the ectopic expression of hTERT, in combination with the simian virus 40 large-T antigen and oncogenic H-ras, led to the creation of tumorigenic cells from normal human fibroblasts. Because telomerase expression is found in 80-90% of human cancers, 18 it has become an attractive target for the treatment of neoplastic tumors. Indeed, recent observations have demonstrated that the expression of a mutant catalytic subunit of human telomerase resulted in complete inhibition of telomerase activity, reduction of telomere length and death of tumor cells. 33 Further insight into the central role of telomeres and telomerase in cellular senescence and immortality came from studies on transgenic mice lacking the telomerase RNA subunit (mTR or mTerc). 34 In those telomerase-deficient mice, progressive telomere shortening was detected with each generation. After six generations, both male and female mice were sterile and exhibited hematopoietic insufficiencies and defects in other organ systems. 35 These results indicate that even in mice, the loss of telomere repeats is incompatible with cell proliferation in the long term.
Properties of hematopoietic stem cells
The limited lifespan of mature blood cells requires their continuous production, which in adults exceeds 10 12 cells/day. The calculated output of up to 4 Â 10 16 cells over the lifetime of an individual requires pluripotent hematopoietic stem cells (HSCs), characterized by a very high replicative capacity (for a review, see Lansdorp 36 ). HSCs are defined as multipotential cells, their frequency is less than 1 in 10 000 nucleated cells in the bone marrow and they are thought to have the capability to undergo self-renewal. 37, 38 The functional properties of HSCs are difficult to investigate, both because of their low frequency and, more importantly, because of the lack of a well-defined phenotype. Heterogeneity among CD34 þ 38À human candidate stem cells is considerable and in vitro expansion data investigating the proliferative potential of individual stem cells argue in favor of a hierarchy even within the most primitive stem cell compartment. 39 The fate of individual daughter cells (after stem cell divisions) seems to be intrinsically determined, linked to cell cycle properties and unevenly distributed among daughter cells via asymmetric cell division. [39] [40] [41] [42] [43] For the above-mentioned reasons, HSCs are very difficult to purify, and as a consequence, little is known about the physiological turnover of these cells during life.
Telomeres and stem cell turnover in normal hematopoiesis
In vitro studies on the role of telomere biology for HSC expansion HSCs of different ontogenetic age vary significantly in terms of proliferative potential and cell cycle activity, 44 ,45 a phenomenon that seems to correlate with a measurable loss of telomeric repeats when comparing fetal liver with cord blood and cord blood to adult bone marrow cells. 46, 47 In normal HSCs, telomerase seems unable to prevent telomere shortening with replication, probably because of the low level of expression. [48] [49] [50] Telomerase expression is upregulated with cell cycle activation, and as a consequence, expression levels are higher in more committed CD34 þ 38 þ progenitors compared to the CD34 þ 38À population. 50 Whether telomerase expression or other positive and/or negative regulators actually lead to a different rate of telomere shortening per PD in HSCs compared to other somatic cells remains to be elucidated. Recently, stem cell expansion with preserved telomerase activity for 18 weeks in culture was achieved purely by optimizations of culture conditions, including cytokine and stromal support. 51 Similarly, in vivo administration of granulocyte-colony-stimulating factor has been postulated to attenuate telomere attrition, thereby contributing to preservation of telomere integrity in transplanted stem cells. However, in analogy with data in the murine system 52 (see below), ectopic overexpression of hTERT in vitro, despite measurable induction of telomerase activity, does not prevent proliferation-associated telomere shortening nor increase proliferative capacity in human hematopoietic cells, [53] [54] [55] emphasizing the concept of cell-type-specific differences in telomere maintenance.
In sequential analysis of individual highly proliferative in vitro expanded CD34 þ 38À fetal liver cells, 39 we showed replicative telomere shortening with a rate of telomere repeats lost per PD that was in the range observed for normal (telomerase-negative) somatic cells. Interestingly, in keeping with studies performed in fibroblasts, 56 both telomere length and the rate of telomere shortening were highly heterogeneous between chromosome arms (unpublished data). In follow-up studies performed using cord blood-derived CD34 þ 38À cells, we recently showed that growth kinetics are not only linked to the proliferation potential of the individual stem cell clone but also to telomere length and gene expression pattern. 57 One could hypothesize that telomere length in CD34 þ 38À cells might be used to identify immature sub-populations in the HSC compartment (Figure 1) . However, unfortunately, lack of well-established methodology that would allow the enrichment of viable CD34 þ 38À cells based on telomere length has so far prevented this parameter from being prospectively validated as a potential novel stem cell marker.
Telomere length and stem cell turnover in vivo Turnover of normal HSC in vivo estimated from telomere fluorescence measurements. The number of cell divisions required for differentiation of a mature peripheral blood (PB) cell from a primitive, multipotential stem cell might be different for the individual lineage but should be constant over the lifetime of an individual. In line with this assumption, analysis of human HSC sub-populations revealed a decline in telomere length from immature CD34 þ 38À to more committed CD34 þ 38 þ cells. 58 As PB myeloid cells are characterized by a relatively short lifespan, one could hypothesize that, at any point of time, the telomere length in these cells reflects the telomere length of the HSC they are derived from. Indeed, comparative analysis revealed that telomere length in bone marrow aspirates as compared to peripheral blood leukocytes (PBLs) and mononuclear cells (MNCs) as well as in CD34 þ cells compared to PBSC harvests was shown to be closely correlated. 59 However, lymphocytes included in the MNC fraction of PB display a pronounced heterogeneity in both telomere length and telomerase activity dependent on both their B-or T-cellular origin as well as their naive or memory phenotype, respectively. [60] [61] [62] [63] [64] Therefore, telomere length needs to be measured in defined Telomere length dynamics in hematopoietic stem cells in vitro and in vivo TH Brümmendorf and S Balabanov leukocyte sub-populations such as granulocytes (or monocytes), before one can estimate the turnover of at least those cells in the HSC compartment that are actively contributing to hematopoiesis at a certain point in time.
The primary determinant of telomere length in individuals has been shown to be genetic by twin studies, 63, 65, 66 strain-specific variation in telomere length in different mice strains 67 and the fact that telomere length on specific chromosome arms from different tissues of the same individual are similar. 68 This leads to the conclusion that ideally, longitudinal studies that avoid inter-individual variability and ideally cover the whole age range of an individual species would be required to appropriately investigate the dynamics of telomere shortening with age.
Hematopoietic phenotype of the telomerase knockout (mTerc À/À ) mouse. As outlined above, mice genetically deficient for mTerc lack telomerase activity and show telomere shortening at a rate of 4-5 kb per mouse generation. 34 Depending on their genetic background, late-generation mTerc À/À mice are infertile, show reduced viability and exhibit defects in highly proliferative tissues, 35 such as the hematopoietic system. 69 In particular, late-generation mTerc À/À B6 mice show splenic atrophy, abnormal hematopoietic function, an impaired B-and T-cell reaction to mitogen stimulation and a defective germinal center reaction following antigen immunization. 70 A significant decrease in the total number of committed progenitors in late-generation as opposed to early-generation mTerc À/À mice has been reported. 35 However, a comparative analysis of the competitive long-term repopulating ability of late-generation mTerc À/À HSCs compared with wild-type controls indicated that under steady-state conditions telomerase deficiency does not seem to impair stem cell function. 71 Murine serial transplantation studies. Significant telomere shortening could be demonstrated in a murine system of serial bone marrow transplantation (BMT) by Allsopp et al. 72 In these studies, telomere shortening correlated well with the number of serial transplantations performed. In follow-up studies, the degree of telomere shortening was found to be more pronounced 71 when HSCs were derived from animals lacking functional telomerase activity (mTRÀ/À as well as mTERTÀ/À). 34, 35 Not unexpectedly, this increased rate of shortening per round of transplantation translated into a reduced number of maximum serial transplantation cycles possible. Taken together, the data were suggestive of telomere-mediated functional exhaustion of the murine HSC pool. 71 However, ectopic overexpression of telomerase in wild-type cells was not sufficient to overcome replicative exhaustion in this serial transplantation assay in general. 52 In view of the pronounced differences in telomere biology between mice and men, 52, 73 these results will need to be confirmed by serial xenogeneic transplantation assays of human HSCs into a murine host. These studies are important in the face of incidental observations of late graft failures in long-term survivors after allogeneic BMT 74 (see below) and the role of telomerase alterations for the incidence of inherited bone marrow failure syndromes like dyskeratosis congenita (DKC). In addition, a better understanding of the role of telomere-mediated replicative exhaustion of HSC in the human setting will be important to anticipate potential hematological side effects of pharmacological inhibition of telomerase activity 75, 76 as a potential new strategy to treat malignant tumors.
Telomere length dynamics and HSC turnover in cats. Cats are considered adult at 1 year of age, which is early in relation to their life expectancy of up to 20 years. Based on these considerations, we followed telomere length in PB cells of Safari cats 77 longitudinally for 12 months, aiming to cover a significant period of growth and development in the life of a young animal. Interestingly, both absolute telomere length and the rate of telomere shortening over time in vivo, but also the rate of telomere shortening per PD in vitro, were found to be around five-to 10-fold higher in the feline as compared to the human system. 78 Based on these results, we estimated a turnover rate of around 30 PD in the feline stem cell compartment in the first year of life.
Kinetics of telomere shortening in sub-populations of human PB cells
In humans, the impact of genetic inter-individual differences in telomere length can only be approached by cross-sectional studies with a sufficient sample size, allowing the identification of potential patterns of telomere length kinetics with age. A number of studies on age-related decline of telomere length in PB cells in healthy donors (mostly used as a control population for patients with particular disease states) have been performed 65, [79] [80] [81] [82] [83] [84] and describe a linear rate of telomere shortening over age, in the range of 25-40 bp/year. In one study, based on the analysis of individuals from three generations of different families ranging from newborns to their grand-parents, a trisegmented decline in telomere length with a steep initial phase of decline and a first break-off point after 4 years was suggested. 83 In accordance with these results, another group described an average rate of shortening of 270 bp/year for the first 3 years of life by sequential analysis of MNC from nine different (HIV-negative) infants of HIV-infected mothers. 85 More recently, we have used telomere fluorescence measurements in defined sub-populations of PB cells. 63 We analyzed telomere length in granulocytes and lymphocytes (including their memory and naive CD4-and CD8-positive subsets) in more than 500 individuals, including 36 pairs of monozygotic and dizygotic twins. Despite the considerable inter-individual variability in telomere length found in this cross-sectional study, we could describe statistically significant differences in the rate of telomere shortening in the first years of life compared to later on, by using bi-segmented linear regression analysis. Both granulocytes and naive T-lymphocytes showed similar rates of telomere shortening, indicating that we were indeed measuring the turnover of a common precursor cell. According to these findings, HSC turnover seems to be at least 20-fold accelerated in the first year of life compared to the years that follow. It remains to be clarified if such a dramatic rate of telomere shortening can still be explained by replicative telomere shortening alone or if other replication-independent regulators of telomere length play a role as suggested by others. 83, 84, [86] [87] [88] Interestingly, these results are in good agreement with our estimate of HSC turnover in cats (30 PD in the first 12 months) and suggest that HSC turnover in early life in cats and in humans is comparable. Interestingly, similar kinetics of telomere shortening were observed over the age range of 0.2-26.5 years in baboons. 89 Recently, by using stochastic simulation of replication rates of HSC in vivo based on telomere length kinetics, Shepherd et al. 90 demonstrated that HSC turnover rates differ quite substantially between vertebrates, ranging from once per 2.5 weeks in mice to once per 8-10 weeks in cats to once per 45 weeks in humans.
Frequent blood donors. Theoretically, the hematopoietic stress resulting from blood donation may be considered minor when based on the daily steady-state production rates for red cells and platelets, which amount to approximately 2 Â 10 11 and 1.5 Â 10 11 , respectively. 91 Nevertheless, the total number of blood cells collected over time from a long-term volunteer donor can add up to numbers equivalent to several years of steady-state blood cell production. 92 Analysis of telomere length in PB cells of volunteer whole blood and apheresis platelet donors, however, neither revealed a difference in telomere length between donor and non-donor nor a correlation between the total number of donations or the total years of donation, respectively. In summary, this study suggests that, based on telomere length analysis, the impact of frequent blood donations on the replicative capacity of the human HSC pool appears insignificant. 92 Telomere biology in disease states associated with increased HSC turnover
Telomere length kinetics after SCT Allogeneic BMT. Telomere shortening after allogeneic BMT or SCT has been a major field of interest, both for researchers focused on immune reconstitution and for stem cell biologists. [93] [94] [95] [96] [97] Pilot studies performed by Wynn et al. 93 and by Notaro et al. 97 compared telomere length in full chimeras after allogeneic BMT to their respective donors. Although using slightly different approaches and cell sources, both groups demonstrated clear differences in telomere length post-transplantation. Wynn et al. 93 reported an average shortening of around 0.4 kb and suggested that this telomere deficit translates into an additional stem cell aging effect caused by the transplantation procedure in the range of 15 years. In addition, Notaro et al., 97 using telomere length measurements on chromosome 7q in granulocytes only, were the first ones to be able to detect a significant inverse correlation between telomere shortening and the number of MNCs infused, supporting the notion that telomere shortening indicates expansion of the stem cell compartment associated with repopulation of the host bone marrow by donor cells post-transplant.
To date, it remains unclear whether continuously increased telomere shortening after transplantation could potentially lead to hematopoietic insufficiency (particularly in situations with continued and/or increased proliferative stress post-transplant) and finally to stem cell exhaustion. However, despite case reports pointing to a role for telomere-mediated stem cell exhaustion post-allogeneic BMT in individual patients, 74 longitudinal follow-up studies, 98, 99 as well as analysis of long-term survivors after allogeneic BMT, 100,101 suggested telomere shortening post-transplant to merely reflect the stem cell expansion required for repopulation of the recipient bone marrow by the donor cells. Telomere shortening also occurs after nonmyeloablative conditioning 102 and there is no published evidence of further accelerated telomere shortening happening in the recipient as compared to the donor after the time point of full hematopoietic reconstitution. These data argue against telomere-mediated replicative exhaustion creating a clinically relevant problem after allogeneic transplantation 95, 103, 104 in adults (reviewed by Brummendorf et al. 105 ). However, one could envision scenarios in which exhaustion of the replicative reserve after allogeneic SCT could potentially become clinically meaningful such as late relapse of (or secondary) malignancy requiring myelotoxic treatment after haploidentical transplantation from an old donor into a young child. Therefore further studies in this area including continued follow-up of long-term survivors after SCT are clearly warranted.
Autologous SCT. Late replicative exhaustion owing to accelerated telomere shortening after autologous peripheral blood stem cell transplantation (PBSCT) has been a concern because of both cytotoxic pretreatment as well as growth factor induced mobilization of progenitor cells. Indeed, some of the studies performed showed significantly shortened telomeres post-as opposed to pre-PBSCT, which in some cases was even more pronounced as compared to the allogeneic transplant setting. 94, [106] [107] [108] However, in a recently published longitudinal study, Bhatia et al. 109 demonstrated initial shortening of telomere length in bone marrow cells after SCT followed by subsequent restoration to pre-SCT levels. Similar to the allogeneic situation, the initial decrease in telomere length post-PBSCT could be explained by the rapid proliferation required for repopulation of the bone marrow by the transplanted (allogeneic or autologous) stem cells. The authors hypothesize that the recovery in telomere length 1 year or later after SCT could be explained by long-term reconstitution via (previously quiescent) HSC populations, which are unaffected by transplantation-associated replicative shortening of telomere length.
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DKC: a genetic model disorder linking disrupted telomere maintenance with bone marrow failure. Dramatically reduced telomere length has recently been described in patients with DKC, 110 a progressive bone marrow failure syndrome characterized by abnormal skin pigmentation, leukoplakia and nail dystrophy. X-linked, autosomal-recessive and autosomal-dominant inheritance have been found in different pedigrees. The clinical spectrum of the disease is wide ranging, from severely affected individuals in the first decade of life (as in Hoyeraal-Hreidarsson syndrome 111, 112 ) to asymptomatic patients with only slight changes in blood cell counts. 113 Interestingly, the X-linked form of the disease is owing to missense mutations in the gene DKC1 on the long arm of the X-chromosome. 114 The affected protein, dyskerin, is a nucleolar protein that is associated with hTR. 115 Furthermore, in patients with autosomal-dominant DKC, both deletions as well as mutations involving hTR have recently been described. 116 Although mutations in the DKC1 or TERC gene can only be identified in less than 50% of the patients 117 and have been shown to represent a rarity in patients with acquired aplastic anemia (AA), these findings strongly point to a link between bone marrow failure syndromes and telomere biology. Just recently, a mutation in a functional SP1 binding site of telomerase has been identified as an additional mechanism 118 linking a defined mutation to a telomere phenotype in an acquired bone marrow failure syndrome, here paroxysmal nocturnal hemoglobinuria (PNH). 119, 120 Aquired bone marrow failure syndromes Both acquired AA and PNH are thought to result from damage to the stem and progenitor compartment caused by autoaggressive T cells. In AA, pancytopenia, the hallmark of the disease, correlates well with the decreased numbers of immature hematopoietic cells measured either as CD34 þ cells or as colony-forming cells [121] [122] [123] as well as with stem/progenitor cells. 124, 125 Although some recovery may occur in patients successfully treated with immunosuppression, in most patients a significant deficit in stem cell numbers persists despite apparent hematological recovery. 126, 127 The increased risk for development of late clonal disorders such as PNH (25% at 15 years 128 ), myelodysplastic syndromes (MDS, probability ranging from 10 to 47%) and acute leukemia could be owing to impaired immunosurveillance or alternatively owing to cell intrinsic factors associated with premature aging or genetic instability in the bone marrow stem/progenitor cell compartment eventually leading to clonal hematopoiesis.
Indeed, telomere lengths in granulocytes from patients with AA were not only found to be significantly shorter compared to age-adjusted controls 82 but the degree of telomere shortening was significantly correlated with the degree of (pan-)cytopenia observed.
129 Surprisingly however, telomere length in granulocytes from AA patients who had recovered after immunosuppressive therapy did not differ significantly from controls, whereas untreated patients and non-responders with persistent severe pancytopenia showed marked and significant telomere shortening. 129 These results support extensive proliferation of HSC in subgroups of AA patients (reviewed by Brummendorf 130 ). However, the crucial question as to whether telomere shortening was a secondary phenomenon reflecting increased HSC turnover as a consequence of (potentially auto-immune mediated) damage to the stem cell compartment, or alternatively, bone marrow failure was (at least partly) caused by telomere-mediated replicative exhaustion of the stem cell pool remains unanswered.
Support for the latter hypothesis came from anecdotal observations of mutations found in the telomerase mRNA gene (hTERC) in hematopoietic cells from patients with acquired bone marrow failure. 131 However, the low frequency of these mutations (two out of 150 patients with AA, none out of 13 patients with PNH) suggests that cryptic DKC rarely seems to be the cause of otherwise clinically typical bone marrow failure syndromes. 132 However, recently heterozygous mutations in the TERT gene, although also a rare event, have been shown to impair telomerase activity by haploinsufficiency and may thus be risk factors for marrow failure. 133 PNH is an acquired clonal disorder of the HSC. Somatic mutations in the X-linked PIG-A gene result in a deficiency of one (or more) HSC and their respective progeny to synthesize a glycolipid embedded in the cell membrane bilayer, the socalled glycosylphosphatidylinositol (GPI) anchor. Clinically, the disease is characterized by intravascular hemolysis, increased incidence of thrombosis and bone marrow failure as well as an increased risk of (secondary) clonal disorders. 134 Today, the favored hypothesis is based on the assumption that PNH evolution is based on an autoimmune-mediated damage to the GPI( þ ) HSC compartment providing for a selective advantage of GPI(À) HSC (reviewed by Karadimitris and Luzzatto and Dun et al. 135, 136 ). This selection process might lead to interindividual differences in terms of residual replicative capacity of the remaining HSC, which, in addition, is affected by disease severity, response to treatment, previous treatments, age of the patient and others (Figure 2 ). Whether a cell intrinsic property of GPI-HSC contributes to disease evolution via positive selection remains controversial. Although some evidence for autoreactive T-cell clones has been published, 137 the definite target antigen of these cells on HSC has not been demonstrated to date. Furthermore, the potential molecular basis of the growth advantage in the GPI-deficient clone in PNH discussed by some groups as well as the reason for clonal evolution from AA to MDS and acute leukemia remain to be elucidated. Karadimitris et al., 119 using Southern blotting, reported significantly shortened telomere length in granulocytes from 10 patients with PNH and found no bias for telomere shortening towards either GPI( þ ) or GPI(À) cells. However, using the Proaerolysin flow-FISH methodology, 120 we found GPI(À) granulocytes to be significantly shorter than their GPI( þ ) counterparts. Interestingly, both GPI(À) as well as GPI( þ ) cells from PNH patients showed significant telomere shortening compared to age-matched normal GPI( þ ) healthy individuals. 120 These data support the growth advantage hypothesis, which argues that a depletion of the GPI( þ ) HSC compartment is (at least partly) compensated by hyperproliferation of residual GPI(À) cells resulting in accelerated telomere shortening in this population. Alternatively, accelerated replication-independent telomere shortening could account for this phenomenon, for example, owing to increased sensitivity to oxidative stress 86 or altered expression of telomerase-/telomere-binding proteins.
Telomere biology in disease states associated with increased HSC turnover owing to malignant transformation of HSC Chronic myeloid leukemia and Ph-negative chronic myeloproliferative disorders Chronic myeloid leukemia (CML) represents a model disorder to study the role of telomere biology for disease progression in a malignant stem cell disorder (Figure 3) . First, the malignant HSC, Telomere length dynamics in hematopoietic stem cells in vitro and in vivo TH Brümmendorf and S Balabanov defined by the Bcr-Abl translocation, is characterized by an increased cellular turnover. Secondly, the disease is characterized clinically by a relatively stable chronic phase (CP) that can last for many years but is always followed by an acceleration phase (AP) after an unpredictable period of time. The AP of the disease followed by blast crisis (BC) is associated with increased genetic instability and with the acquisition of additional cytogenetic abnormalities and mutations that are responsible for the altered and more aggressive growth pattern of the malignant clone. To investigate the impact of telomere biology on disease progression in malignant HSC in this disease, we comparatively analyzed telomere length in (Philadelphiapositive (Ph) þ ) PBL and PhÀ T-lymphocytes, respectively. We found that telomeres in malignant cells were indeed significantly shorter than PhÀ T-lymphocytes. 138 In line with these findings, cytogenetic and molecular response after imatinib therapy 139, 140 is correlated with an increase in mean telomere length (shown in (1); Figure 3 ). This observation reflects a steadily increasing fraction of PhÀ cells (with normal or only slightly reduced telomere length) contributing to the PB cell pool in treated patients. 141 Furthermore, age-adjusted telomere shortening was found to be correlated both with disease stage, remaining duration of CP before onset of BC 138 and Hasford risk score. 142 One might speculate that upregulation of telomerase confers a selective growth advantage to the malignant subclone by preventing it from further replication-dependent telomere shortening and as a consequence from cellular senescence or crisis. Based on this hypothesis, specific inhibition of telomerase activity might represent an attractive therapeutic approach in this clinical scenario (shown in (2); Figure 3 ). However, as correction for cell cycle status has revealed that telomerase activity might in fact not be elevated on a cell-to-cell basis, 143 telomerase upregulation observed in patients might actually only reflect the increased proportion of cycling cells in the bone marrow. These data are supported by the lack of overexpression of hTERT as well as a reduction of hTR expression levels found in CP-CML samples by quantitative reverse transcriptase polymerase chain reaction. 143 Taken together, the role of telomerase expression for disease progression in CML, including the analysis of telomere-as well as telomerase-binding proteins for this process, requires further investigation.
Compared to CML, Bcr-Abl-negative chronic myeloproliferative disorders (CMPDs), namely polycythemia vera and essential thrombocythemia represent clonally more heterogeneous disorders. By taking advantage of random inactivation of X-chromosome-linked polymorphisms, clonality has been studied in CMPDs, initially by Fialkow and coworkers, [144] [145] [146] [147] and later by other groups using different polymorphisms. [148] [149] [150] Interestingly, it seems as if clonality in CMPD is also linked to both shortened telomeres 151, 152 as well as to significantly increased levels of telomerase activity 153 as opposed to nonclonal CMPD and normal bone marrow cells. Moreover, similar to what has been described in CML, 138 telomere length seems to be significantly reduced in (presumably clonal) myeloid cells as opposed to (non-clonal) T-lymphocytes. 152 Just recently a defined mutation Val617Phe in the JAK2 locus has been described as being typical for this group of diseases. [154] [155] [156] This mutation occurs at a different frequency in the different CMPD subtypes. 157 Apart from serving as a potential novel target for treatment approaches similar to imatinib in CML, the JAK2 mutational status might potentially allow subclassification of Bcr-Abl-negative CMPDs into JAK2-mutated vs -unmutated subgroups in the near future. 158 Whether JAK2 mutational status is linked to clonality and, as a consequence, to telomere biology will need to be demonstrated.
MDS and AML
Cytogenetic aberrations are among the most important independent prognostic factors in adult AML. 159 It is tempting to speculate that telomere-mediated genetic instability might be involved in the evolution of secondary karyotypic abnormalities as well as of prognostic relevance for disease evolution in patients with normal karyotype. Indeed, several studies have investigated telomerase activity and telomere length in total MNC from patients with MDS and AML. [160] [161] [162] [163] [164] [165] [166] [167] Interestingly, telomere shortening was significantly more pronounced in patients with cytogenetic alterations as compared to patients with normal karyotypes. 168 The shortest median telomere length was found in the group with complex karyotypes. Furthermore, within patients with normal karyotypes, the FLT3 mutant/weight ratio was able to discriminate between patients with shorter and longer telomeres, indicating that not only cytogenetic aberrations but also mutations within cell cycle relevant genes may lead to telomere shortening. HTERT was most frequently overexpressed in patients with complex karyotypes, followed by patients with non-complex karyotypes and patients without karyotypic changes. 168 This might suggest that with increasing karyotypic abnormalities, telomere attrition, either by replication-dependent or -independent mechanisms, becomes more pronounced and, as a consequence, telomerase upregulation becomes essential to prevent replicative senescence of the malignant clone. However, it has recently been suggested that telomerase expression in the context of short telomeres does not necessarily prevent cells from replicative exhaustion. 169 Owing to the uneven distribution of telomere length on individual chromosome arms, 68 critical shortening of telomeres on selected chromosome arms could promote the formation of chromosomal aberrations and thus be of importance for clonal evolution even if the average telomere length in an individual cell remains well above the critical level of shortening. 170 As suggested, distinct groups of AML, which are characterized either by aberrations that theoretically could result from telomere dysfunction (terminal deletions, gains/losses of chromosome parts, non-reciprocal translocations) or aberrations that are unlikely to result from telomere dysfunction (e.g., reciprocal 
Cytogenetic response Figure 3 Model of telomere biology in myeloproliferative disorders, for example, Ph þ CML: link between telomere shortening and disease progression and response to treatment in CML. Treatment with disease-modifying agents, for example, tyrosine kinase inhibitors (as shown). Treatment with telomerase inhibitors (hypothetical).
translocations or inversions) could serve as an ideal model to study the effect of telomere shortening7telomerase activity for this process. 171 
